Bunge raises EPS target to $15 by 2030, unveils $3B buyback

Bunge raised its mid-cycle diluted EPS baseline to ~$13 and set a target of at least $15 by end-2030 (vs. LTM EPS $4.93 and analyst FY2026 EPS $8.03), and authorized a $3.0B share repurchase while committing to return >=50% of discretionary cash flow to shareholders. Shares trade at $118.79, up ~60% year-over-year and ~46% over six months, with market cap ~$23B and LTM revenue growth of 32% driven by the Viterra acquisition; the company also closed the IFF soy protein/lecithin deal and cancelled >12M shares (share capital reduced by $123,826.10). Morgan Stanley reiterated Overweight with a $130 PT; operational risk noted after a reported deliberate attack on Bunge’s Dnipro facility.

Analysis

Bunge's strategic pivot toward higher-margin ingredient and protein exposures plus heavier capital returns materially changes the competitive payoff matrix in grains and oilseeds. If management can convert scale into differentiated commercial contracts (premiumization into specialty proteins, branded ingredient supply agreements, captive feedstocks for processing), competitors with narrower balance sheets or less integrated origination networks will face margin compression and potential market-share loss over 12–36 months.

Execution risk is the dominant second-order variable: integration slippage, logistics churn, and commodity price swings can erase much of the headline EPS uplift. The most acute catalysts to watch in the next 3–12 months are (a) cadence and aggressiveness of buybacks (which will mechanically lift EPS and shrink float), and (b) observable margin progression in the midstream/ingredient P&Ls versus cyclical crush margins — a divergence there would validate the strategy, convergence would reverse sentiment.

Geopolitical and regulatory inputs create asymmetric outcomes. Upside is driven by sustained demand for higher‑value protein ingredients and favorable biofuel or trade policy that widens crush spreads; downside is a quick soybean price shock, shipping/logistics bottlenecks, or any regulatory restriction on repurchases that forces redeployment into lower‑return capex. Practically, the market is already paying a premium for a multi-year execution story; the trade is timing execution proofs rather than the press release itself.

Key Decisions for Investors

• Long BG (size 3–5% portfolio) — target +30% total return over 12–24 months, stop -12%. Rationale: buyback-driven EPS lift plus scale in higher‑value ingredients. Hedge operational downside with a 25% notional short in soybean futures (or SOYB) to protect crush‑margin sensitivity for the first 6–12 months.
• Buy BG 18‑month call spread (buy 1x 30% OTM call / sell 1x 60% OTM call) — max loss = premium paid, asymmetric upside if management delivers synergies in 12–24 months. Use this to express upside while capping capital at ~1% portfolio risk.
• Pair trade: long BG / short ADM (equal notional) — 12‑month horizon, expected relative outperformance 10–20% if ingredient premiumization and origination scale translate into higher margins. Risk: broad sector sell-off or synchronized crush-margin improvement at ADM that erases relative spread; keep position small and monitor monthly margin releases.
• Event hedge: if buyback cadence is light in next two quarters, reduce net exposure and rotate proceeds into specialty protein or ingredient names with visible contract revenues; conversely, add to BG on sequentially accelerating buyback execution or upward analyst revisions.